Table of Contents

1. Zuclopenthixol
   1. Pharmacist Assessment Report
   2. Zuclopenthixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Canada Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Zuclopenthixol: From Schizophrenia to Retinal Dystrophy with or without Extraocular Anomalies

One-Sentence Summary

Zuclopenthixol is an antipsychotic originally used to treat schizophrenia. The TxGNN model predicts it may be effective for retinal dystrophy with or without extraocular anomalies, but no clinical trials and no publications currently support this prediction, so it rests on the model’s computation alone.

Quick Overview

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, zuclopenthixol is a thioxanthene antipsychotic that antagonizes dopamine D1/D2 and 5-HT2A receptors, with additional alpha-1 and H1 activity. Its efficacy has been established in schizophrenia, a psychiatric condition.

No plausible mechanistic link to retinal dystrophy has been established. Retinal dystrophies are genetically heterogeneous inherited disorders, and nothing in the available data connects dopamine antagonism to their disease pathways. Phenothiazine-class drugs are also known to carry a risk of retinal toxicity (pigmentary retinopathy), which argues against benefit rather than for it.

The high TxGNN score (0.9999, rank 219) is a TxGNN model (deep learning) prediction only. It should be treated as a hypothesis-generating signal, not as evidence of efficacy.

Other predicted indications (all L5, all Hold):

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

All three authorizations are valid single-ingredient products.

Safety Considerations

Please refer to the package insert for safety information.

No drug-drug interaction records were found in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by the TxGNN model score. There are no clinical trials or publications, and no mechanistic link between dopamine/5-HT2A antagonism and retinal dystrophy. The known risk of retinal toxicity with related drug classes points in the opposite direction.

To proceed, the following is needed:

• Mechanism of action data for zuclopenthixol (for example, from DrugBank)
• Health Canada package insert warnings and contraindications, which are required before any safety screening
• Preclinical or mechanistic evidence linking zuclopenthixol to retinal dystrophy pathways
• An assessment of ocular safety, given the retinal toxicity concern with related antipsychotics
• Approved indication text, dosage forms and manufacturers for the three Canadian authorizations

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zolpidem
   1. Pharmacist Assessment Report
   2. Zolpidem: Benign paroxysmal torticollis of infancy
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Canada Market Information
   9. Safety Considerations
   10. Other Predicted Indications (Low Evidence)
   11. Conclusion and Next Steps
   12. Disclaimer

Zolpidem: Benign paroxysmal torticollis of infancy

One-Sentence Summary

Zolpidem is a sedative-hypnotic originally used to treat insomnia. The TxGNN model predicts it may be effective for benign paroxysmal torticollis of infancy, with no registered clinical trials and 20 publications (including network meta-analyses and clinical guidelines) currently supporting this direction. Because this predicted indication is essentially the same as the drug’s established use, it is better seen as confirmation of an existing indication than as true repurposing.

Quick Overview

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available in the data compiled for this report. Based on the mechanistic assessment, zolpidem is a positive allosteric modulator of the GABA-A receptor with preferential affinity for the alpha-1 subunit. This produces sedative-hypnotic effects.

The publications reviewed describe zolpidem as a “Z-drug” (with zopiclone, eszopiclone and zaleplon) that is widely used for insomnia. They also note that it carries risks of cognitive impairment, falls, dependence and next-day impairment, particularly in older adults.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Canada Market Information

Twelve valid single-ingredient licences are held in total. The remaining seven are other zolpidem ODT products from JAMP, PRO and PMS.

Safety Considerations

• Contraindication signals (from the knowledge graph, not label text): anxiety disorder, neurotic disorder, dysthymic disorder, liver disease, gallbladder disease, obstructive sleep apnea syndrome, sleep apnea syndrome, congenital central hypoventilation syndrome, amnestic disorder, retrograde amnesia, substance-related disorder, substance abuse/dependence, and attention deficit hyperactivity disorder.
• Key warnings (from the mechanistic assessment): complex sleep behaviors (boxed warning), next-day impairment, and increased risk in older adults.
• Drug interactions: 100 interactions were identified. Major interactions include morphine and liposomal morphine. Moderate interactions include opium, bupropion, aprepitant, dexamethasone, cimetidine, clarithromycin, dronabinol, nabilone, metoclopramide, miconazole and clotrimazole. The risk is greatest with other CNS depressants.

Please refer to the package insert for the full label warnings and contraindications.

Other Predicted Indications (Low Evidence)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The predicted indication essentially matches zolpidem’s established use in insomnia, and it is supported by network meta-analyses and clinical guidelines. It is also marketed in Canada under 12 licences. No clinical trials are registered for this specific predicted indication, and the safety burden is significant.

To proceed, the following is needed:

• Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
• Detailed mechanism of action data from DrugBank
• Approved indication text and dosage forms for the Canadian licences
• A risk-management plan for complex sleep behaviors, next-day impairment, use in older adults, and co-prescription with CNS depressants and opioids
• If true repurposing is intended, a clearly distinct target indication, since the two other predictions (benign paroxysmal torticollis of infancy and agoraphobia) lack supporting evidence and should remain on hold

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zolmitriptan
   1. Pharmacist Assessment Report
   2. Zolmitriptan: Atrophoderma vermiculata
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Canada Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Zolmitriptan: Atrophoderma vermiculata

One-Sentence Summary

Zolmitriptan is a triptan (5-HT1B/1D receptor agonist) originally used for the acute treatment of migraine. The TxGNN model predicts it may be effective for atrophoderma vermiculata, but there are currently no registered clinical trials and 18 publications, which are mostly general migraine reviews rather than studies of this specific subtype.

Quick Overview

Why is This Prediction Reasonable?

Zolmitriptan is a selective 5-HT1B/1D receptor agonist that acts both centrally and peripherally. Preclinical work suggests it inhibits trigeminovascular activation in the brain as well as in the periphery. This is the basis for its use in acute migraine attacks, where it relieves headache and associated symptoms such as nausea, photophobia and phonophobia.

The very high TxGNN score (0.9990) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. It is not independent clinical evidence.

An important caution applies. Triptans have historically carried cautionary labeling for basilar-type or brainstem aura because of theoretical concerns about vasoconstriction. No study in the data compiled for this report evaluates zolmitriptan specifically in brainstem aura, so safety must be reviewed before any recommendation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

The publications below are the most relevant of those compiled. None specifically evaluates zolmitriptan in migraine with brainstem aura.

Canada Market Information

Zolmitriptan has 16 valid single-ingredient authorizations in Canada. The approved indication text and dosage forms are not available in the data compiled for this report. Product names suggest nasal spray and orally disintegrating formulations in addition to standard tablets.

The remaining 11 authorizations are generic products, including Sandoz, Teva (OD), Mint, Nat, NRA, Mar, Bio, Jamp and Auro versions.

Safety Considerations

• Contraindication-related conditions (from the knowledge graph, not label text): the drug-disease contraindication links include
  • Cardiovascular and cerebrovascular conditions: coronary artery disease, myocardial infarction, myocardial ischemia, Prinzmetal angina, Wolff-Parkinson-White syndrome, stroke, transient ischemic attack, cerebral infarction, brain ischemia, intracranial arteriosclerosis, vertebrobasilar insufficiency, peripheral vascular disease, Raynaud disease
  • Blood pressure: hypertension
  • Organ disease: kidney disease, liver disease, gallbladder disease
  • Other: ischemic bowel disease, hemoglobinopathy, familial or sporadic hemiplegic migraine
• Drug Interactions: 82 interactions were recorded. Those rated Major include lorcaserin, dolasetron, palonosetron, ondansetron, granisetron, dexfenfluramine, fenfluramine and sibutramine, which are mostly serotonergic agents. Moderate interactions include morphine, cimetidine and obeticholic acid.
• Case report: a published case describes acute myocardial infarction associated with zolmitriptan, consistent with the vasoconstriction concern for triptans.

The package insert warnings and contraindications were not available for this report, so please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The mechanistic link to migraine with brainstem aura is plausible, but there are no clinical trials and no publications that specifically evaluate zolmitriptan in this subtype. The high TxGNN score mainly reflects similarity to the approved migraine indication. Triptans have historically carried cautionary labeling for brainstem aura, and the knowledge graph lists many cerebrovascular contraindications. The other two predicted indications (atrophoderma vermiculata and ulerythema ophryogenesis) have no plausible mechanistic link, no trials and no literature, and should also stay on hold.

To proceed, the following is needed:

• Health Canada package insert warnings and contraindications, especially for basilar-type or brainstem aura (this is a blocking gap for safety screening)
• Detailed mechanism of action data from DrugBank
• A focused literature review and safety assessment for triptan use in brainstem aura, including vasoconstriction and stroke risk
• Approved indication text and dosage forms for the Canadian products
• If the safety review is acceptable, a well-designed clinical study in this specific subtype

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zolbetuximab
   1. Pharmacist Assessment Report
   2. Zolbetuximab
   3. Quick Overview
   4. Canada Market Information
   5. Cytotoxicity
   6. Safety Considerations
   7. Disclaimer

Zolbetuximab

Quick Overview

Canada Market Information

Cytotoxicity

Safety Considerations

Please refer to the package insert for safety information.

The only drug-interaction record compiled is a pharmacology target entry (claudin 18, CLDN18), which is not a drug-drug interaction.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Ziprasidone
   1. Pharmacist Assessment Report
   2. Ziprasidone: Trichotillomania
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Canada Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Ziprasidone: Trichotillomania

One-Sentence Summary

Ziprasidone is an atypical antipsychotic marketed in Canada. The TxGNN model predicts it may be effective for trichotillomania, but no clinical trials and no publications were found for this disease, so the prediction rests on the model score alone.

Quick Overview

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in the data compiled for this report. Based on general pharmacology, ziprasidone blocks dopamine D2 and serotonin 5-HT2A receptors. Both pathways are involved in repetitive and compulsive behaviours, which are central features of trichotillomania.

This link is plausible but unproven. No trial or publication in the compiled data studies ziprasidone in trichotillomania, so the mechanistic argument is a hypothesis, not a finding. The high model score should be read as a prompt for further investigation, not as evidence of efficacy.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Canada Market Information

Eight single-ingredient licences are currently valid, and none are cancelled. The table lists five of them.

Safety Considerations

• Drug Interactions: The interaction screen returned 100 records. Major-level interactions in the listed sample include hydrocortisone, amphotericin B (including the lipid complex form), bupropion and morphine. Several moderate interactions involve antidiabetic drugs (acarbose, metformin, pioglitazone, alogliptin, albiglutide) and anticholinergic agents (atropine, hyoscyamine, glycopyrronium).
• Conditions flagged as cautions for ziprasidone include long QT syndrome, torsades de pointes, sudden cardiac arrest, heart conduction disease, myocardial infarction, orthostatic hypotension, epilepsy, neutropenia, agranulocytosis, diabetes and diabetic ketoacidosis, liver failure and kidney disease. These come from a drug–disease relationship dataset, not from label text.

Please refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for trichotillomania is supported only by a high model score. No trials or literature address this disease, so the evidence level is L5. The D2/5-HT2A mechanism is plausible but untested.

To proceed, the following is needed:

• Mechanism-of-action data for ziprasidone
• Package insert warnings and contraindications from Health Canada, including QTc-related cautions
• A literature search and, if warranted, preclinical or small exploratory clinical data in trichotillomania
• A comparison against existing treatment options for the condition before any clinical development decision

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zinc Sulfate
   1. Pharmacist Assessment Report
   2. Zinc Sulfate: Pharyngitis
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Canada Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Zinc Sulfate: Pharyngitis

One-Sentence Summary

Zinc sulfate is a zinc salt found in a range of single-ingredient products marketed in Canada. The TxGNN model predicts it may be effective for pharyngitis, with a score of 0.9985, but the only randomized trial in pharyngitis itself found no benefit, so evidence remains at L5. One trial of zinc lozenges addressed postoperative sore throat, a related but different condition.

Quick Overview

Why is This Prediction Reasonable?

Detailed mechanism-of-action data are not available for this drug. Zinc is generally thought to act locally on mucous membranes, with possible antiviral and anti-inflammatory effects and support of epithelial repair. This is a plausible but unproven rationale for the throat.

The high TxGNN score is a computational output and is not clinical evidence. The only randomized placebo-controlled trial in pharyngitis itself tested zinc sulfate for radiation-induced oral mucositis and pharyngitis in head and neck cancer patients (PMID 23720981), and it did not show a benefit. The lozenge trial concerns sore throat after intubation, which is a different cause from infectious pharyngitis. Because no study showing benefit directly addresses the predicted disease, the evidence level is L5.

Clinical Trial Evidence

Literature Evidence

Canada Market Information

Safety Considerations

• Drug Interactions: Interaction data were compiled for 100 interacting drugs. Moderate-level interactions include alendronic acid, risedronic acid, ibandronate, tetracycline and baloxavir marboxil. Most other listed interactions, such as immunosuppressants and corticosteroids, are minor.

For other safety information, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The model score is very high, but the only randomized trial in pharyngitis itself showed no benefit, and the lozenge trial addresses a related but different condition. Evidence therefore stays at L5.

To proceed, the following is needed:

• A well-designed controlled trial in infectious pharyngitis with a defined zinc formulation and dose
• Mechanism-of-action data for zinc in the pharynx
• Package insert warnings and contraindications for the relevant products

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zinc Oxide
   1. Pharmacist Assessment Report
   2. Zinc Oxide: Acne (disease)
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Canada Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Zinc Oxide: Acne (disease)

One-Sentence Summary

Zinc oxide is a topical skin protectant originally used for conditions such as dermatitis, fungal skin infections, diaper-area irritation, hemorrhoids and burns. The TxGNN model predicts it may be effective for acne, but there are no registered clinical trials and only 3 publications (a review, a preclinical study and a small clinical study), so this remains a research question.

Quick Overview

Why is This Prediction Reasonable?

Detailed mechanism of action data is not currently available. Based on known information, zinc oxide is a topical zinc preparation whose use in several inflammatory and irritated skin conditions is well established, and mechanistically it may be applicable to acne.

Zinc is generally thought to have antibacterial effects, including against Cutibacterium acnes, partly through zinc ion release and reactive oxygen species generation. It also has mild anti-inflammatory, sebum-regulating and astringent properties. Its existing use in dermatitis and other skin conditions suggests it is tolerated on the skin.

This link rests on general zinc biology, not on a documented drug-specific mechanism. The very high TxGNN score is a computational prediction only and does not replace clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Canada Market Information

Dosage forms and approved indication texts are not available for these products. The main ones are:

The remaining authorizations are mostly sunscreens and skin-care products (for example, ELTAMD UV products, OLAY SENSITIVE and COPPERTONE sunscreen stick).

Safety Considerations

• Disease associations flagged in the knowledge graph (not label text): The model’s drug-disease contraindication links include hypertension, benign prostatic hyperplasia, sickle cell anemia, primary hyperoxaluria, hereditary hemochromatosis, hemosiderosis, iron metabolism disease, Wilson disease, coronary artery disease, sudden cardiac arrest, heart conduction disease, hyperthyroidism, Graves disease, thyrotoxicosis and anxiety. These are model-derived links and are unlikely to reflect topical use directly. They should be checked against the official labels.
• Drug Interactions: No interaction records were found.

Please refer to the package insert for further safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The acne prediction has a high model score but no registered clinical trials, and the only supporting literature is a review, a preclinical study and a small clinical study. The mechanistic link relies on general zinc biology. The other four predictions (anorectal stricture, anal polyp, papillary conjunctivitis, postinfectious vasculitis) have no supporting evidence at all and are weaker still.

To proceed, the following is needed:

• Package insert warnings and contraindications from Health Canada, so safety screening can proceed
• Mechanism of action data for zinc oxide (for example, from DrugBank)
• Confirmation of whether the 2004 split-face study actually tested zinc oxide
• Controlled clinical studies of topical zinc oxide in acne, with a defined formulation and concentration

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zinc Acetate
   1. Pharmacist Assessment Report
   2. Zinc Acetate: From Dermatitis and Wilson Disease to Severe Nonproliferative Diabetic Retinopathy
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Canada Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Zinc Acetate: From Dermatitis and Wilson Disease to Severe Nonproliferative Diabetic Retinopathy

One-Sentence Summary

Zinc acetate is a zinc salt used for skin conditions (such as dermatitis and rash) and for metal-metabolism disorders such as Wilson disease. The TxGNN model predicts it may be effective for severe nonproliferative diabetic retinopathy, but no clinical trials and no publications currently support this prediction. It rests on the model’s score alone.

Quick Overview

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, zinc acetate is a zinc salt used in skin conditions and in disorders of copper and iron metabolism, and its mechanism may be applicable to the predicted indication.

One speculative link is that zinc is a cofactor for antioxidant enzymes such as copper/zinc superoxide dismutase (Cu/Zn-SOD). Oxidative stress contributes to retinal injury in diabetes, so this could be relevant. No trial or publication in the data compiled for this report supports this link, and it should be treated as a hypothesis only.

The predicted indications ranked 2 to 10 are also supported only by model scores or by indirect literature. They include bronchitis, diabetic retinopathy (closely related to the lead prediction rather than independent evidence), several skin and autoimmune conditions, and urinary tract infection.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available for the lead prediction.

Indirect literature exists only for lower-ranked predictions:

Canada Market Information

All four licences are valid authorizations. The product names suggest topical itch and bug-bite products.

Safety Considerations

• Contraindications (from the knowledge graph, not label text): inherited porphyria, porphyrin metabolism disease and porphyria.
• Drug Interactions: 100 interactions were found in the DDI query. The ones listed in the data are mostly Minor and include immunosuppressants and biologics (abatacept, adalimumab, azathioprine) and corticosteroids (hydrocortisone, dexamethasone, betamethasone, triamcinolone). Moderate interactions include:
  • Bisphosphonates: alendronic acid, risedronic acid, ibandronate
  • Tetracycline
  • Baloxavir marboxil

  These moderate interactions are consistent with zinc binding other drugs and reducing their absorption, but the data do not state a mechanism.

Package insert warnings and contraindications from Health Canada have not been obtained. Please refer to the package insert for full safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction for severe nonproliferative diabetic retinopathy has a high model score (0.9997) but no supporting clinical trials or literature (Evidence Level L5). The Canadian licences cover only topical itch and bug-bite products, which are not an obvious fit for a retinal disease. Label-based safety data are also missing.

To proceed, the following is needed:

• Health Canada package insert warnings and contraindications for safety screening
• Detailed mechanism of action data, for example from DrugBank
• A literature search on zinc and diabetic retinopathy, including preclinical oxidative-stress studies
• Assessment of route and formulation compatibility, since the marketed products are topical and a retinal indication would likely need a different route
• Review of the porphyria contraindication signal and the moderate drug interactions

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zidovudine
   1. Pharmacist Assessment Report
   2. Zidovudine: From HIV Infection and AIDS to Feline Acquired Immunodeficiency Syndrome
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Canada Market Information
   9. Safety Considerations
   10. Conclusion and Next Steps
   11. Disclaimer

Zidovudine: From HIV Infection and AIDS to Feline Acquired Immunodeficiency Syndrome

One-Sentence Summary

Zidovudine is a nucleoside reverse transcriptase inhibitor originally used to treat HIV infection and AIDS in humans. The TxGNN model predicts it may be effective for feline acquired immunodeficiency syndrome (FIV/FeLV-related disease in cats). This direction currently rests on 0 registered clinical trials and 19 publications, which are almost entirely animal or veterinary studies.

Quick Overview

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available in the data compiled for this report. Zidovudine is, however, a known nucleoside reverse transcriptase inhibitor (NRTI). It is phosphorylated in cells and blocks viral DNA synthesis by chain termination.

Feline immunodeficiency virus (FIV) is a lentivirus whose reverse transcriptase is closely related to that of HIV-1. This makes the prediction biologically plausible. FIV-infected cats are also widely used as an animal model of HIV infection.

Preclinical and veterinary reports describe lower plasma virus titres, reduced provirus burden and some immune benefit in treated cats. Results are mixed, though. Zidovudine did not prevent infection in several studies, and benefits were often not sustained after treatment stopped.

This is a veterinary indication, not a new human use. Its value for human medicine is mainly as a model for HIV research.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Canada Market Information

A sixth authorization, 02502801 (JAMP LAMIVUDINE / ZIDOVUDINE), is also valid. All six licences are currently valid. Dosage form and approved-indication text were not available for these products. These are human-use products.

Safety Considerations

• Contraindications and risk conditions from the knowledge graph (not label text): These are the disease associations recorded in the TxGNN knowledge graph:
  • Haematological: neutropenia, agranulocytosis, anaemia (including macrocytic anaemia)
  • Hepatic: liver failure, liver disease, fatty liver disease, non-alcoholic steatohepatitis, gallbladder disease
  • Metabolic: lactic acidosis, hypertriglyceridaemia, obesity disorders
  • Muscle: myopathy, myositis, dermatomyositis, muscular disease, skeletal muscle disease, familial periodic paralysis
  • Other: kidney disease, pancreatitis, pyoureter
• Drug Interactions: The interaction screen returned 100 interactions in total, of which 20 were reviewed here.
  • Moderate: amphotericin B (including the cholesteryl sulfate and lipid complex forms), corticosteroids (betamethasone, budesonide, dexamethasone, hydrocortisone, prednisolone, prednisone, triamcinolone), statins (rosuvastatin, simvastatin), naltrexone, orlistat
  • Minor: cimetidine, clarithromycin
  • Unknown severity: pantoprazole, omeprazole, morphine, metformin
• Veterinary toxicity: A toxicity study in FeLV-infected cats (PMID 2163339) is available and should be reviewed before any dose planning.

Please refer to the package insert for label warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is very high (0.9996), but support is limited to animal and veterinary studies (L4). There are no registered clinical trials. The indication is veterinary and does not extend human use of the drug.

Two other predictions for this drug have much stronger evidence: congenital HIV and AIDS-related complex. Both have Phase 3 trial support and were rated “Proceed with Guardrails”. However, they fall within the drug’s existing HIV/AIDS indication rather than being true repurposing.

To proceed, the following is needed:

• Mechanism-of-action data for the drug
• Package insert warnings and contraindications from Health Canada
• Clarification of whether a veterinary indication is within the programme’s scope
• Controlled veterinary trials with defined endpoints, if the feline indication is pursued
• A review of the toxicity data from cat studies, including haematological effects

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

Table of Contents

1. Zanubrutinib
   1. Pharmacist Assessment Report
   2. Zanubrutinib: From Mantle Cell Lymphoma to Myeloid Leukemia
   3. One-Sentence Summary
   4. Quick Overview
   5. Why is This Prediction Reasonable?
   6. Clinical Trial Evidence
   7. Literature Evidence
   8. Canada Market Information
   9. Cytotoxicity
   10. Safety Considerations
   11. Conclusion and Next Steps
   12. Disclaimer

Zanubrutinib: From Mantle Cell Lymphoma to Myeloid Leukemia

One-Sentence Summary

Zanubrutinib is a BTK inhibitor originally used for B-cell malignancies such as mantle cell lymphoma. The TxGNN model predicts it may be effective for myeloid leukemia, but this is mainly a computational prediction. Only 1 clinical trial (Phase 1, where zanubrutinib is a combination partner) and 10 publications, mostly about B-cell diseases, are linked to it, so direct supporting evidence is very limited.

Quick Overview

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Based on known information, zanubrutinib is a next-generation Bruton tyrosine kinase (BTK) inhibitor. Its efficacy in B-cell malignancies has been established, and the data compiled for this report suggest that it may be mechanistically relevant to other blood cancers.

The link to myeloid leukemia is indirect. BTK is expressed in some myeloid cells and AML blasts and may contribute to survival signaling. However, there is no direct clinical evidence of benefit. The publications compiled for this report concern chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Waldenström macroglobulinemia and BTK inhibitor safety. These are all B-cell diseases, not myeloid leukemia. The high score (0.9965) should be read as a model prediction, not as proof of efficacy.

Clinical Trial Evidence

Literature Evidence

None of these studies tests zanubrutinib in myeloid leukemia.

Canada Market Information

Cytotoxicity

Safety Considerations

• Drug Interactions: The interaction screening returned 100 interacting drugs. Major-level examples include aprepitant, acetylsalicylic acid, dexamethasone, clarithromycin, cobicistat, deferasirox, deferiprone, samarium (153Sm) lexidronam, ibritumomab tiuxetan and tositumomab (I-131). Moderate-level examples include cimetidine, miconazole, clotrimazole, fenfluramine, sibutramine and troglitazone.
• Other safety signals from the literature: Reports describe hepatitis B virus reactivation in patients on BTK inhibitors, and hypogammaglobulinemia with increased infection risk.

Package insert warnings and contraindications were not available for this report, so please refer to the package insert for them.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests mainly on the model score. The only linked trial is a Phase 1 combination study with no direct myeloid leukemia data, and the literature concerns B-cell diseases. Evidence level is L4, and the mechanistic link to myeloid leukemia is indirect.

To proceed, the following is needed:

• Mechanism of action data and a clearer analysis of BTK dependence in myeloid leukemia (AML)
• Preclinical studies or clinical data on zanubrutinib in myeloid leukemia
• Verification of the actual cohort composition of NCT05665530
• Package insert warnings and contraindications from Health Canada, which are required before safety screening
• Approved indication and dosage form details for the two Canadian DINs

  Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.